Inclusion Criteria:

          1. Eastern Cooperative Oncology Group (ECOG) Performance status ≤2.

          2. Age ≥18 years.

          3. Histologically-confirmed adenocarcinoma of the prostate.

          4. Treated with continuous androgen ablative therapy (either surgical castration or LHRH
             agonist/antagonist).

          5. Documented castrate level of serum testosterone (<50 ng/dl).

          6. Metastatic disease radiographically documented by CT or bone scan.

          7. Must have had disease progression while on abiraterone acetate alone or abiraterone
             acetate in combination with other ADT.:

          8. PSA progression defined as an increase in PSA, as determined by 2 separate
             measurements taken at least 1 week apart And/ Or Radiographic disease progression,
             based on RECIST 1.1 in patients with measurable soft tissue lesions or PCWG3 for
             patients with bone disease

          9. Screening PSA must be ≥ 1.0 ng/mL.

         10. Patients with soft tissue lesion amenable to biopsy must agree to biopsy collection
             pre-treatment and at a defined point on treatment to perform tumor tissue analysis.

         11. No prior treatment with enzalutamide, apalutamide, darolutamide, or other
             investigational androgen receptor (AR) targeted treatment is allowed.

         12. Prior treatment with testosterone is allowed.

         13. Prior treatment with docetaxel (≤ 6 doses)for hormone-sensitive prostate cancer is
             allowed.

         14. Prior treatment with Provenge vaccine and 223Radium (Xofigo) is allowed if >4 weeks
             from last dose.

         15. Patients must be withdrawn from abiraterone for ≥ 2 weeks.

         16. Attempts must be made to wean patients off prednisone and be off therapy for ≥ 1 week
             prior to starting therapy. Patients who cannot be weaned due to symptoms may continue
             on lowest dose of prednisone achieved during weaning period.

         17. Acceptable liver function:

             Bilirubin < 2.5 times institutional upper limit of normal (ULN) aspartate transaminase
             (AST) (SGOT) and aka alanine aminotransferase (ALT) (SGPT) < 2.5 times ULN

         18. Acceptable renal function:

             Serum creatinine < 2.5 times ULN

         19. Acceptable hematologic status:

             Absolute neutrophil count (ANC) ≥ 1500 cells/mm3 (1.5 ×109/L) Platelet count ≥ 100,000
             platelet/mm3 (100 ×109/L) Hemoglobin ≥ 9 g/dL.

         20. At least 4 weeks since prior radiation or chemotherapy.

         21. Ability to understand and willingness to sign a written informed consent document.

        Exclusion Criteria:

          1. Pain due to metastatic prostate cancer requiring treatment intervention.

          2. ECOG Performance status ≥3

          3. Prior treatment with enzalutamide is prohibited.

          4. Prior chemotherapy with docetaxel or cabazitaxel for castration resistant prostate
             cancer is prohibited.

          5. Requires urinary self-catheterization for voiding due to obstruction secondary to
             prostatic enlargement well documented to be due to prostate cancer or benign prostatic
             hyperplasia (BPH). Patients with indwelling Foley or suprapubic catheter for
             obstructive symptoms are eligible.

          6. Evidence of disease in sites or extent that, in the opinion of the investigator, would
             put the patient at risk from therapy with testosterone (e.g. femoral metastases with
             concern over fracture risk, severe and extensive spinal metastases with concern over
             spinal cord compression, extensive liver metastases).

          7. Evidence of serious and/or unstable pre-existing medical, psychiatric or other
             condition (including laboratory abnormalities) that could interfere with patient
             safety or provision of informed consent to participate in this study.

          8. Active uncontrolled infection, including known history of HIV/AIDS or hepatitis B or
             C.

          9. Any psychological, familial, sociological, or geographical condition that could
             potentially interfere with compliance with the study protocol and follow-up schedule.

         10. Patients receiving anticoagulation therapy with Coumadin are not eligible for study.
             [Patients on non-coumadin anticoagulants (Lovenox, Xarelto, etc.) are eligible for
             study. Patients on Coumadin who can be transitioned to lovenox prior to starting study
             treatments will be eligible].

         11. Patients are excluded with prior history of a thromboembolic event within the last 12
             months that is not being treated with systemic anticoagulation.

         12. Hematocrit >51%, untreated severe obstructive sleep apnea, uncontrolled or poorly
             controlled heart failure [per Endocrine Society Clinical Practice Guidelines (34)]

         13. Patients allergic to sesame seed oil or cottonseed oil are excluded.

         14. Major surgery (eg, requiring general anesthesia) within 3 weeks before screening, or
             has not fully recovered from prior surgery (ie, unhealed wound). Note: subjects with
             planned surgical procedures to be conducted under local anesthesia may participate.